Rockwell Medical, Inc.
NCM: RMTILive Quote
📈 ZcoreAI Score
Our AI model analyzes Rockwell Medical, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RMTI Z-Score →About Rockwell Medical, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, the company offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
📊 Fundamental Analysis
Rockwell Medical, Inc. demonstrates a profit margin of -7.7%, which is below the sector average, suggesting competitive pressure.
The company recently reported -25.6% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -15.3%, which indicates that capital utilization is currently under pressure.
At a current price of $0.91, RMTI currently trades near the bottom of its 52-week range (10%), indicating potential value or weakness (Range: $0.78 - $2.10).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$35.85M
Trailing P/E
--
Forward P/E
13.00
Beta (5Y)
1.71
52W High
$2.10
52W Low
$0.78
Avg Volume
714K
Day High
Day Low